Opinion statement
Therapeutic management of patients with inflammatory bowel diseases (IBDs) has, for years, been tailored towards monitoring patient clinical presentation as a way to gauge therapeutic management. With the advent of newer biological agents, treatment and management have begun to focus on more objective rather than subjective parameters. These objective parameters include endoscopic targets and focus on the impact of mucosal healing, radiologic and histologic targets, patient reported outcomes, and use of non-invasive biomarkers. However, a recent consensus statement has identified clinical/patient-reported outcome (PRO) remission and endoscopic remission (defined as a Mayo endoscopic subscore of 0–1) as the target for UC with histological remission being an adjunctive goal. For CD, clinical/PRO remission defined as resolution of abdominal pain and diarrhea/altered bowel habit and endoscopic remission, defined as resolution of ulceration at ileocolonoscopy, and resolution of findings of inflammation on cross-sectional imaging in patients who cannot be adequately assessed with ileocolonoscopy were the primary targets. Biomarker remission (normal C-reactive protein (CRP) and calprotectin) was considered as an adjunctive target. This approach requires continuous monitoring and therapeutic adjustments with an aim to achieve the target. This article attempts to review the most updated literature regarding the treat to target approach and thus provides current recommendations and supported evidence.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–19.
Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.
Mandel MD, Miheller P, Mullner K, Golovics PA, Lakatos PL. Have biologics changed the natural history of Crohn’s disease. Dig Dis. 2014;32:351–9.
•• Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1042–15. This article discusses the definition and utilization of treat to target approach and how that can be implemented in current clinical practice for IBD management. It gives a very clear description that sets a foundation for the rest of the currently written article
Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn’s disease: a systematic review and meta-analysis. World J Gastroenterol. 2013;19:3866–71.
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.
Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008;43:948–54.
Yang CH, Ding J, Gao Y, Chen X, Yang ZB, Xiao SD. Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn’s disease. J Dig Dis. 2011;12:99–104.
Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol. 2009;15:3504–10.
Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375–81, e1. quiz e13-4
Sandborn WJ, Hanauer S, Van Assche G, Panes J, Wilson S, Petersson J, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014;8(9):27–35.
Hefti MM, Chessin DB, Harpaz NH, Steinhagen RM, Ullman TA. Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis. Dis Colon Rectum. 2009;52:193–7.
Kuriyama M, Kato J, Fujimoto T, Nasu J, Miyaike J, Morita T, et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient’s clinical background. Dis Colon Rectum. 2006;49:1307–15.
Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–35.22.
Walsh A, Palmer R, Travis S. Mucosal healing as a target therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointestinal Endoscopy Clin N Am. 2014;24:367–78.
Froslie KF, Jahnsen J, Moum BA, Vatn MH, Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295–301.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Belgian Inflammatory Bowel Disease Research, North-Holland Gut ClubMucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8. quiz e10-1
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–9.36.
Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–489. e3.
Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.
Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947–53.
Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806–16.
Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982–1018.
Rimola J, Ordas I, Rodriguez S, Garcia-Bosch O, Aceituno M, Llach J, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759–68.
Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guerenu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Aliment Pharmacol Ther. 2011;34:125–45.
Ordas I, Rimola J, Rodriguez S, Paredes JM, Martinez-Perez MJ, Blanc E, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014;146:374–82, e1.
Plumb AA, Menys A, Russo E, Prezzi D, Bhatnagar G, Vega R, Halligan S, Orchard TR, Taylor SA. Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn’s disease. Aliment Pharmacol Ther. 2015;42:343–55.
•• Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat to target. Am J Gastroenterol. 2015;110:1324–38. This article discusses the STRIDE trial that gives recommendations for utilization of objective markers based on current literature. The recommendations are based on a collaborative effort by international organization of gastroenterologists and provide great insight into future IBD guidelines
Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817–26, e2.
Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–5.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn’s disease management after intestinal resection: a randomized trial. Lancet. 2015;385:1406–17.
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Kre-jany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease following surgery. Gastroenterology. 2015;148:938–947.e1.
Bondjemah V, Mary JY, Jones J, Sandborn W, Schoepfer A, Louis E, et al. P133 fecal calprotectin and CRP as biomarkers of endoscopic activity in Crohn’s disease: a meta-study. J Crohn’s Colitis. 2012;6:S63.
D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–24.
Lemann M, Colombel J, Grimaud J, Bouhnik Y, Laharie D, Dupas J. Fecal calprotectin and high sensitivity C-reactive protein levels to predict mucosal healing in patients with Crohn’s disease. A subanalysis of the STORI study. Gut. 2010;59:A80.49.
Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–15.
• Bouguen G, Levesque BG, Pola S, et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014;20:231–9. . This article gives substantial evidence regarding use of endoscopy to assess ulcerative colitis-associated mucosal healing and as a target to treat method
• Bouguen G, Levesque BG, Pola S, et al. Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:978–85. This article gives substantial evidence regarding use of endoscopy to assess Crohn’s disease-associated mucosal healing and as a target to treat method
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Umar Darr declares that he has no conflict of interest.
Nabeel Khan has received speaker’s bureau fees from AbbVie and Janssen; grants from Takeda, Pfizer, and Luitpold; and advisory board support from GI Health Foundation.
Human and animal rights and informed consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Inflammatory Bowel Disease
Rights and permissions
About this article
Cite this article
Darr, U., Khan, N. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. Curr Treat Options Gastro 15, 116–125 (2017). https://doi.org/10.1007/s11938-017-0130-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11938-017-0130-6